(Q34989829)

5 August 2017

1 reference

title

Regional therapy of hepatic metastases (English)

1 reference

5 August 2017

Douglas L Fraker

1

1 reference

5 August 2017

Michael Soulen

series ordinal

2

1 reference

5 August 2017

publication date

1 August 2002

1 reference

Hematology / Oncology Clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

16

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

947-967

1 reference

Pharmacologic rationale for hepatic arterial therapy.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Tumor and liver drug uptake following hepatic artery and portal vein infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Towards gene therapy for colorectal liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

The role of irinotecan in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Regional chemotherapy of colorectal cancer metastatic to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Alternating Hepatic Intra-Arterial Floxuridine and Fluorouracil: A Less Toxic Regimen for Treatment of Liver Metastases From Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Transcatheter oily chemoembolization of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Hepatic chemoembolization: safety with portal vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Determinants of postembolization syndrome after hepatic chemoembolization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Risk factors for liver abscess formation after hepatic chemoembolization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Colorectal metastases to the liver: selective chemoembolization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

First experience and technical aspects of isolated liver perfusion for extensive liver metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Hepatic cryosurgery in treating colorectal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Complications of hepatic cryosurgery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Radiofrequency ablation of the liver: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Laparoscopic radiofrequency ablation of primary and metastatic liver tumors. Technical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

Radiofrequency Ablation of 100 Hepatic Metastases with a Mean Follow-Up of More Than 1 Year

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900039-4

7 January 2021

10.1016/S0889-8588(02)00039-4

Identifiers

DOI

1 reference

5 August 2017

1 reference